We validated the proposed method on (A) a high amplicon density dataset of eight tumor samples for which array comparative genomic hybridization (array CGH) profiles were available, (B) a high amplicon density dataset of 30 ErbB2-positive ovarian cancer samples and (C) a low amplicon density dataset of 30 tumors, coupled with single nucleotide polymorphism (SNP) array data. The gene discussed is ERBB2; the disease is neoplasm.